Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00005950
What this trial is testing

506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma

Who this might be right for
Angioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell Lymphoma+7 more
National Cancer Institute (NCI) 111
Large-scale testing (Phase 3)Study completedNCT01231412
What this trial is testing

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAggressive Non-Hodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center 174
Not applicableEnded earlyNCT02273856
What this trial is testing

Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)

Who this might be right for
Indolent Non Hodgkin's Lymphoma (iNHL)Chronic Lymphocytic Leukaemia (CLL)
Astellas Pharma International B.V. 25
Early research (Phase 1)Looking for participantsNCT05418088
What this trial is testing

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more
Sumithira Vasu 54
Testing effectiveness (Phase 2)Study completedNCT01682044
What this trial is testing

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Who this might be right for
Contiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular LymphomaContiguous Stage II Grade 3 Follicular Lymphoma+30 more
Roswell Park Cancer Institute 20
Early research (Phase 1)Study completedNCT00012207
What this trial is testing

Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Fred Hutchinson Cancer Center 12
Large-scale testing (Phase 3)Study completedNCT03078855
What this trial is testing

Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Follicular LymphomaSmall Lymphocytic LymphomaMarginal Zone Lymphoma+1 more
Jonathan Friedberg 211
Testing effectiveness (Phase 2)Ended earlyNCT02258529
What this trial is testing

Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Who this might be right for
Follicular LymphomaSmall Lymphocytic Lymphoma
Gilead Sciences 10
Testing effectiveness (Phase 2)UnknownNCT00927797
What this trial is testing

Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)

Who this might be right for
Immunocytoma/Morbus WaldenströmB-Cell Non-Hodgkin's LymphomaB-Cell Chronic Lymphocytic Leukemia
Heidelberg University 185
Early research (Phase 1)Study completedNCT01317901
What this trial is testing

TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

Who this might be right for
B-cell Small Lymphocytic Lymphoma Recurrent
Aptevo Therapeutics 12
Testing effectiveness (Phase 2)Study completedNCT01206777
What this trial is testing

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Who this might be right for
Indolent or Intermediate Grade B-cell Malignancy
Ohio State University Comprehensive Cancer Center 52
Large-scale testing (Phase 3)Ended earlyNCT01732926
What this trial is testing

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Who this might be right for
Indolent Non-Hodgkin's Lymphomas
Gilead Sciences 475
Early research (Phase 1)Study completedNCT00963274
What this trial is testing

Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Who this might be right for
LeukemiaLymphoma
Virginia Commonwealth University 18
Early research (Phase 1)Study completedNCT01088048
What this trial is testing

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin's LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma
Gilead Sciences 241
Early research (Phase 1)Active Not RecruitingNCT04464200
What this trial is testing

19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell LymphomaTransformed Follicular Lymphoma to Diffuse Large B Cell Lymphoma+6 more
Memorial Sloan Kettering Cancer Center 30
Early research (Phase 1)Study completedNCT00621452
What this trial is testing

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell Lymphoma+8 more
Fred Hutchinson Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT01282424
What this trial is testing

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

Who this might be right for
Follicular LymphomaSmall Lymphocytic LymphomaLymphoplasmacytic Lymphoma+1 more
Gilead Sciences 125
Testing effectiveness (Phase 2)Study completedNCT00764517
What this trial is testing

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Indolent Adult Non-Hodgkin Lymphoma+1 more
OHSU Knight Cancer Institute 57
Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)Ended earlyNCT01796470
What this trial is testing

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell Lymphoma+1 more
Gilead Sciences 66
Next Page